Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: LIMD2

Summary for LIMD2

Gene information	Gene symbol	LIMD2
	Ensembl ID	ENSG00000136490
	Entrez ID	80774
	Gene name	LIM domain containing 2
	Synonyms	MGC10986
	Gene type	protein_coding
	UniProtAcc	Q9BT23

Top

Dataset with differentially expressed gene: LIMD2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.254535	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.568125	4.02e-22
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.273095	1.07e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	-0.440533	2.81e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.269299	1.18e-17
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD8+ T cells	0.345649	0.00e+00
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	CD4+ T cells	0.369792	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	0.612706	2.72e-19
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	0.306428	5.42e-04
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.553314	2.00e-11
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	NK cells	0.505451	1.70e-03
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.521643	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	0.263704	9.12e-09
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.466098	2.30e-20
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD8+ T cells	0.297335	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	-0.376035	4.90e-08
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.309659	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.33959	1.72e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.431669	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.497794	4.00e-13
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-2.32973	1.11e-14
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.356328	4.64e-03
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	0.501571	1.64e-20
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.404784	3.09e-09
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.307542	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	0.501853	4.51e-02
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	0.852845	0.00e+00
GSE115251	Kelly cell line	Cell line	Neuroblastoma	Neuroblastoma	Targeted therapy	TAE684	NA	Malignant cells	-0.306606	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-0.340838	0.00e+00

Top

Expression of LIMD2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to LIMD2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating LIMD2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
LIMD2	hsa-miR-4500	94.3305	NM_030576
LIMD2	hsa-miR-4664-5p	94.2817	NM_030576
LIMD2	hsa-miR-342-5p	93.5153	NM_030576
LIMD2	hsa-miR-6796-5p	92.5983	NM_030576
LIMD2	hsa-miR-24-3p	90.6454	NM_030576
LIMD2	hsa-let-7i-5p	90.408	NM_030576
LIMD2	hsa-let-7e-5p	90.408	NM_030576
LIMD2	hsa-let-7c-5p	90.408	NM_030576
LIMD2	hsa-let-7d-5p	90.408	NM_030576
LIMD2	hsa-miR-4458	90.408	NM_030576
LIMD2	hsa-let-7f-5p	90.408	NM_030576
LIMD2	hsa-let-7b-5p	90.408	NM_030576
LIMD2	hsa-let-7g-5p	90.408	NM_030576
LIMD2	hsa-miR-98-5p	90.408	NM_030576
LIMD2	hsa-let-7a-5p	90.408	NM_030576
LIMD2	hsa-miR-7156-3p	90.3835	NM_030576
LIMD2	hsa-miR-488-5p	90.1973	NM_030576
LIMD2	hsa-miR-5003-5p	88.899	NM_030576
LIMD2	hsa-miR-6799-3p	88.7405	NM_030576
LIMD2	hsa-miR-3173-5p	87.5031	NM_030576
LIMD2	hsa-miR-548an	87.0604	NM_030576
LIMD2	hsa-miR-433-3p	86.4069	NM_030576
LIMD2	hsa-miR-3135b	85.8114	NM_030576
LIMD2	hsa-miR-1260a	85.0679	NM_030576
LIMD2	hsa-miR-1260b	85.0679	NM_030576
LIMD2	hsa-miR-6127	82.7861	NM_030576
LIMD2	hsa-miR-608	82.3808	NM_030576
LIMD2	hsa-miR-4651	82.3808	NM_030576
LIMD2	hsa-miR-34a-5p	80.6365	NM_030576
LIMD2	hsa-miR-449a	80.6365	NM_030576
LIMD2	hsa-miR-6763-5p	80.4549	NM_030576
LIMD2	hsa-miR-4447	80.1569	NM_030576

Page: 1

Top

Motifs and transcription factors (TFs) regulating LIMD2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
LIMD2	taipale_tf_pairs__ETV5_HOXA2_RSCGGWAATKR_CAP	ETV5; HOXA2 (directAnnotation).
LIMD2	taipale_tf_pairs__HOXB2_ETV4_ACCGGAAATGAN_CAP	ETV4; HOXB2 (directAnnotation).
LIMD2	hdpi__NFIX	NFIX (directAnnotation).
LIMD2	transfac_pro__M03813	POU3F3 (directAnnotation).
LIMD2	hocomoco__MNX1_HUMAN.H11MO.0.D	MNX1 (directAnnotation).
LIMD2	hdpi__ZNF193	ZSCAN9 (directAnnotation).
LIMD2	hdpi__FOXM1	FOXM1 (directAnnotation).
LIMD2	hocomoco__OTX1_HUMAN.H11MO.0.D	OTX1 (directAnnotation).
LIMD2	transfac_pro__M02843	BBX (inferredBy_Orthology).
LIMD2	taipale_tf_pairs__TEAD4_HOXA13_RCATWCCNNNNNNTTTAYNNN_CAP_repr	HOXA13; TEAD4 (directAnnotation).
LIMD2	swissregulon__hs__SPI1	SPI1 (directAnnotation).
LIMD2	metacluster_167.7	IRF8 (inferredBy_Orthology).
LIMD2	transfac_pro__M02269	FEV (directAnnotation).
LIMD2	metacluster_119.1	ZNF677 (directAnnotation).
LIMD2	tfdimers__MD00342	IRF1; YY1 (directAnnotation).
LIMD2	metacluster_2.4	ZIM3; ZIM3; ZIM3; ZIM3 (directAnnotation).
LIMD2	tfdimers__MD00561	CRX (directAnnotation).
LIMD2	kznf__ZBTB26_Schmitges2016_ChIP-seq	ZBTB26 (directAnnotation).
LIMD2	transfac_pro__M02865	GMEB1 (inferredBy_Orthology).
LIMD2	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
LIMD2	taipale_tf_pairs__ETS2_RCCGGAAGTG_HT	ETS2 (directAnnotation).
LIMD2	hdpi__FLI1	FLI1 (directAnnotation).
LIMD2	kznf__ZNF383_Imbeault2017_RP_RCADE	ZNF383 (directAnnotation).
LIMD2	hocomoco__FOXJ3_HUMAN.H11MO.1.B	FOXJ3 (directAnnotation).
LIMD2	transfac_pro__M06332	ZNF585A (directAnnotation).
LIMD2	metacluster_74.6	HNF1A (directAnnotation).
LIMD2	hdpi__ZNF695	ZNF695 (directAnnotation).
LIMD2	metacluster_69.2	DMRT1; DMRT1 (directAnnotation). DMRTB1; DMRTB1 (inferredBy_Orthology).
LIMD2	tfdimers__MD00421	ELF3; POU5F1 (directAnnotation).
LIMD2	tfdimers__MD00076	HNF1A; HNF1B; PPARG (directAnnotation).
LIMD2	transfac_pro__M06018	ZNF233 (directAnnotation).
LIMD2	hdpi__ZBTB4	ZBTB4 (directAnnotation).
LIMD2	metacluster_130.13	BRCA1 (directAnnotation).
LIMD2	tfdimers__MD00554	CUX1; EP300 (directAnnotation).
LIMD2	hdpi__RAX	RAX (directAnnotation).
LIMD2	taipale_tf_pairs__FOXJ3_TBX21_WAACAACACMY_CAP_repr	FOXJ3; TBX21 (directAnnotation).
LIMD2	tfdimers__MD00601	HOXA13; NFIA; NFIC (directAnnotation).
LIMD2	transfac_pro__M05941	ZNF471 (directAnnotation).
LIMD2	tfdimers__MD00041	CRX; HMBOX1 (directAnnotation).
LIMD2	tfdimers__MD00210	CDX2; HMBOX1 (directAnnotation).
LIMD2	tfdimers__MD00160	CRX; RAX (directAnnotation).
LIMD2	metacluster_175.6	GRHL1; GRHL1; GRHL1; GRHL1; TFCP2 (directAnnotation).
LIMD2	tfdimers__MD00157	MYB; TLX2 (directAnnotation).
LIMD2	transfac_pro__M08811	FOXL2 (directAnnotation).
LIMD2	tfdimers__MD00549	CRX (directAnnotation).
LIMD2	tfdimers__MD00126	NKX6-2 (directAnnotation).
LIMD2	swissregulon__hs__FUBP1	FUBP1 (directAnnotation).
LIMD2	tfdimers__MD00416	HNF1A; HNF1B (directAnnotation).
LIMD2	tfdimers__MD00075	FOXO4; NANOG (directAnnotation).
LIMD2	kznf__ZSCAN29_TF_Evolution_PBM	ZSCAN29 (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."